NASH Drug Pipeline & Market Overview, 2020 - Almost 80 Drug Candidates Involved - ResearchAndMarkets.com

DUBLIN--()--The "NASH Drug Pipeline and Market Overview" report has been added to ResearchAndMarkets.com's offering.

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate.

In addition, the report provides the following data:

  • Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day Supply
  • NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)

In creating its market forecast, the analyst discusses the indicators that needed to be evaluated to create this estimate, commenting on:

  • NASH Disease Incidence and Prevalence
  • NAFLD Incidence and Prevalence
  • Risk Factor Evaluation
  • Pricing Trends
  • Liver Transplant Statistics and Trends
  • Expected Market Penetration
  • Global Treatment Options and Emerging Therapies

Key Topics Covered:

Chapter 1: Executive Summary

  • Introduction
  • Market Summary
  • Competitive Summary

Chapter 2: NASH

  • Overview

Chapter 3: Products in Development

  • Introduction
  • Products in Development

Chapter 4: Market Opportunity

  • Overview
  • Market Forecast Indicators
  • NASH Disease Incidence and Prevalence
  • NAFLD Incidence and Prevalence
  • Risk Factor Evaluation
  • Pricing Trends
  • Liver Transplant Statistics and Trends
  • Expected Market Penetration
  • Global Treatment Options and Emerging Therapies
  • Competitive Overview

Companies Mentioned

  • Allergan
  • Galectin
  • Genfit
  • Gilead
  • Immuron
  • Intercept
  • Madrigal

For more information about this report visit https://www.researchandmarkets.com/r/gv65fi

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900